Elevai Labs
ELAB

$0.3058

1.93%

Market Cap: $6.36M

About: Elevai Labs Inc is a California-based physician-dispensed skincare company with a focus on modernizing aesthetic skincare. It has commercialized ELEVAI Exosomes a next-generation, patent-pending technology used in its ELEVAI flagship products.

Employees: 18

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

134% more capital invested

Capital invested by funds: $37.1K [Q1] → $86.9K (+$49.8K) [Q2]

100% more funds holding

Funds holding: 2 [Q1] → 4 (+2) [Q2]

0.49% more ownership

Funds ownership: 0.31% [Q1] → 0.8% (+0.49%) [Q2]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for ELAB.

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about ELAB published over the past 30 days

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Results for E-Series Exosome Technology in Potential Melasma Applications

Case Studies Highlight Potential of Elevai Exosome Technology in Melasma Care When Used with Laser Therapy. Early Results Show Synergistic Effects of Elevai Exosomes™ and Laser Treatments for Melasma Improvement, With No Recurrence After Six Months.

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Results for E-Series Exosome Technology in Potential Melasma Applications

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Encouraging Data Results Indicating Potential for Hair Restoration Using Proprietary Exosome Technology

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc. Announces Encouraging Research Data Results Indicating Potential for Hair Restoration Using Proprietary

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Encouraging Data Results Indicating Potential for Hair Restoration Using Proprietary Exosome Technology

Elevai Labs Inc. Files Combination Patents with Yuva Biosciences for Breakthrough Hair and Scalp Care Technology Utilizing YuvaBioⓇ Y100™ Mitochondrial Innovation and Elevai Exosomes™

Elevai Labs Inc. Files Combination Patents with Yuva Biosciences for Breakthrough Hair and Scalp Care Technology Utilizing YuvaBioⓇ Y100™ Mitochondria

Elevai Labs Inc. Files Combination Patents with Yuva Biosciences for Breakthrough Hair and Scalp Care Technology Utilizing YuvaBioⓇ Y100™ Mitochondrial Innovation and Elevai Exosomes™

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Data Results with Completion of Clinical Study of Elevai Enfinity™ Topical Exosome Serum

NEWPORT BEACH, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, announces the completion of a clinical study examining the effectiveness of Elevai exosomes on facial appearance.

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Data Results with Completion of Clinical Study of Elevai Enfinity™ Topical Exosome Serum

Elevai Labs Inc. Subsidiary, Elevai Research Inc., Announces Preliminary Positive Research Data Highlighting the Potential of Proprietary Exosome Technology for Skin Health Applications

Preliminary data from the research study in partnership with Dalhousie University demonstrates that Elevai's hUMSC derived exosomes (“ELEVAI exosomes™”) contain over 800 proteins that are associated with wound healing, immunomodulation and remodeling of the skin's extracellular matrix (“ECM”). ELEVAI exosomes™ protein profile detected as part of this study was statistically significant and notably enriched compared to 54 previously published sets of exosome protein data.

Elevai Labs Inc. Subsidiary, Elevai Research Inc., Announces Preliminary Positive Research Data Highlighting the Potential of Proprietary Exosome Technology for Skin Health Applications

Elevai Labs Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

NEWPORT BEACH, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, today reported financial results for the second quarter ended June 30, 2024 and provided a business update.

Elevai Labs Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhD

Professor of Medicine at the University of California, Los Angeles (UCLA), where he serves as Director of the UCLA Metabolism Research Theme. Over 180 publications in the field of obesity & metabolism, along with multiple NIH-funded projects as Principal Investigator.

Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhD

Top 4 Risk Off Stocks You'll Regret Missing In July

The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies. `

Top 4 Risk Off Stocks You'll Regret Missing In July

Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs

NEWPORT BEACH, Calif., June 14, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, announced the formation of a new Scientific Advisory Board to support the advancement of EL-22, a first-in-class engineered probiotic approach, to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists.

Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs

Elevai Labs Inc Subsidiary, Elevai Biosciences, to Present at the UCLA LA-BEST 2024 Conference

NEWPORT BEACH, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, announced that Chief Executive Officer Dr. Jordan R.

Elevai Labs Inc Subsidiary, Elevai Biosciences, to Present at the UCLA LA-BEST 2024 Conference

See News Rankings